Antibodies under a microscope

DA032

Anti-2019-nCoV Spike mAb (IgG&IgM Positive Control)

Description

The product is intended for in vitro diagnostic use in the quality control of serum on clinical chemistry and immunoassay systems. The assayed liquid protein controls are for the control of accuracy. For TRFIA assay, antibody can be diluted to 1:50-1:100, and dilution rate should be adjusted based on different testing method.

Target

2019-nCoV Spike

Isotypes/Mimetics

Human IgG, Human IgM

Animal-Derived Biomaterials Used

No

Sequence Available

Yes

Original Discovery Method

Unknown

Antibody/Binder Origins

Animal-free discovery, Unknown discovery source/method, In vitro recombinant expression, Animal-derived biomaterials used in production or final formulation